{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:35:12Z","timestamp":1777908912299,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Research Foundation of Peking University First Hospital","award":["2017QN23"],"award-info":[{"award-number":["2017QN23"]}]},{"name":"National Key Research & Development Project of China","award":["2016YFC1301304"],"award-info":[{"award-number":["2016YFC1301304"]}]},{"name":"National Science & Technology Support Program of China","award":["2012BAI37B05"],"award-info":[{"award-number":["2012BAI37B05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aspirin is the key treatment in the secondary prevention of atherosclerotic cardiovascular disease. High on-treatment platelet reactivity (HTPR) to aspirin has been reported to partially account for the enhanced risk of thrombotic events. In particular, HTPR has been described more frequently among elderly patients. The aim of this study was to identify the clinical and biological factors associated with HTPR in a real-life elderly population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, elderly patients with atherosclerotic cardiovascular disease on regular aspirin treatment were enrolled. Cardiovascular risk factors, routine biological parameters, comorbidities, and concomitant medications were recorded. The upper quartile of the platelet aggregation rate, determined by light transmission aggregometry with arachidonic acid, was defined as the HTPR group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 304 patients were included (mean age 77\u2009\u00b1\u20098\u2009years, 76% men). Patients in the HTPR group were older than the patients in the non-HTPR group (mean age: 79\u2009\u00b1\u20097 vs. 76\u2009\u00b1\u20098\u2009years,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). Patients with moderately decreased estimated glomerular filtration rate (eGFR) had a higher frequency of HTPR than patients with slightly decreased eGFR or normal eGFR (35.8, 22.5, 12.2%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). In multivariate analysis, an independent risk factor for HTPR was the eGFR (OR: 0.984, 95% CI: 0.980\u20130.988,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Advanced age and decreased eGFR are correlated with poor pharmacodynamic response to aspirin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12877-021-02018-y","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T05:08:09Z","timestamp":1611292089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Wenyi","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9736-9864","authenticated-orcid":false,"given":"Meilin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"issue":"25 Pt B","key":"2018_CR1","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey MC, Blum CB, Eckel RH, et al. ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2018_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12877-018-0777-4","volume":"18","author":"TT Lin","year":"2018","unstructured":"Lin TT, Lai HY, Chan KA, Yang YY, Lai CL, Lai MS. Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. BMC Geriatr. 2018;18(1):86.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2018_CR3","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12872-018-0858-5","volume":"18","author":"YT Bazargani","year":"2018","unstructured":"Bazargani YT, Ugurlu M, de Boer A, Leufkens H, Mantel-Teeuwisse AK. Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovasc Disord. 2018;18(1):126.","journal-title":"BMC Cardiovasc Disord"},{"issue":"1 Suppl","key":"2018_CR4","doi-asserted-by":"publisher","first-page":"39S","DOI":"10.1378\/chest.119.1_suppl.39S","volume":"119","author":"C Patrono","year":"2001","unstructured":"Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1 Suppl):39S\u201363S.","journal-title":"Chest."},{"issue":"1","key":"2018_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","volume":"66","author":"C Patrono","year":"2015","unstructured":"Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol. 2015;66(1):74\u201385.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2018_CR6","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.amjcard.2006.05.041","volume":"98","author":"R Marcucci","year":"2006","unstructured":"Marcucci R, Paniccia R, Antonucci E, Gori AM, Fedi S, Giglioli C, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol. 2006;98(9):1156\u20139.","journal-title":"Am J Cardiol"},{"issue":"9","key":"2018_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jacc.2014.05.049","volume":"64","author":"K Mayer","year":"2014","unstructured":"Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. J Am Coll Cardiol. 2014;64(9):863\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"2018_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.vph.2015.03.018","volume":"67-69","author":"AA Pettersen","year":"2015","unstructured":"Pettersen AA, Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vasc Pharmacol. 2015;67-69:6\u20139.","journal-title":"Vasc Pharmacol"},{"issue":"1","key":"2018_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1538-7836.2009.03644.x","volume":"8","author":"T Gremmel","year":"2010","unstructured":"Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. J Thromb Haemost. 2010;8(1):37\u201342.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2018_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11239-019-01873-2","volume":"48","author":"M Verdoia","year":"2019","unstructured":"Verdoia M, Pergolini P, Nardin M, Rolla R, Tonon F, Kedhi E, et al. Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. J Thromb Thrombolysis. 2019;48(3):413\u201321.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2018_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","volume":"72","author":"TD Warner","year":"2011","unstructured":"Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72(4):619\u201333.","journal-title":"Br J Clin Pharmacol"},{"key":"2018_CR12","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2147\/CIA.S138592","volume":"12","author":"JW Zhang","year":"2017","unstructured":"Zhang JW, Liu WW, McCaffrey TA, He XQ, Liang WY, Chen XH, et al. Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease. Clin Interv Aging. 2017;12:1271\u20139.","journal-title":"Clin Interv Aging"},{"issue":"4","key":"2018_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2018_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jth.13211","volume":"14","author":"A Polzin","year":"2016","unstructured":"Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, et al. Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemost. 2016;14(2):375\u201380.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2018_CR15","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","volume":"55","author":"DJ Angiolillo","year":"2010","unstructured":"Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55(11):1139\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"2018_CR16","doi-asserted-by":"publisher","first-page":"108773","DOI":"10.1016\/j.biopha.2019.108773","volume":"113","author":"ZM Feng","year":"2019","unstructured":"Feng ZM, Lin YQ, Deng BQ, Shu XR, Ke X, Nie RQ. Pharmacodynamic changes of platelet reactivity status in patients with chronic kidney disease after coronary artery stenting. Biomed Pharmacother. 2019;113:108773.","journal-title":"Biomed Pharmacother"},{"key":"2018_CR17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.vph.2015.10.006","volume":"79","author":"L Barbieri","year":"2016","unstructured":"Barbieri L, Pergolini P, Verdoia M, Rolla R, Nardin M, Marino P, et al. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vasc Pharmacol. 2016;79:11\u20135.","journal-title":"Vasc Pharmacol"},{"issue":"3","key":"2018_CR18","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1016\/j.thromres.2012.06.026","volume":"130","author":"AD Blann","year":"2012","unstructured":"Blann AD, Kuzniatsova N, Velu S, Lip GY. Renal function and aspirin resistance in patients with coronary artery disease. Thromb Res. 2012;130(3):e103\u20136.","journal-title":"Thromb Res"},{"issue":"4","key":"2018_CR19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.thromres.2011.07.019","volume":"129","author":"M Wurtz","year":"2012","unstructured":"Wurtz M, Wulff LN, Grove EL, Kristensen SD, Hvas AM. Influence of renal function and platelet turnover on the antiplatelet effect of aspirin. Thromb Res. 2012;129(4):434\u201340.","journal-title":"Thromb Res"},{"issue":"2","key":"2018_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.ajkd.2003.10.037","volume":"43","author":"MJ Landray","year":"2004","unstructured":"Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis. 2004;43(2):244\u201353.","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"2018_CR21","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","volume":"129","author":"K Yang","year":"2017","unstructured":"Yang K, Du C, Wang X, Li F, Xu Y, Wang S, et al. Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice. Blood. 2017;129(19):2667\u201379.","journal-title":"Blood."},{"issue":"2","key":"2018_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.numecd.2019.09.018","volume":"30","author":"M Verdoia","year":"2020","unstructured":"Verdoia M, Rolla R, Negro F, Tonon F, Pergolini P, Nardin M, et al. Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor. Nutr Metab Cardiovasc Dis. 2020;30(2):292\u20139.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"8","key":"2018_CR23","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1093\/ndt\/gft103","volume":"28","author":"T Gremmel","year":"2013","unstructured":"Gremmel T, Muller M, Steiner S, Seidinger D, Koppensteiner R, Kopp CW, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28(8):2116\u201322.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2018_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/jth.13177","volume":"14","author":"M Verdoia","year":"2016","unstructured":"Verdoia M, Pergolini P, Rolla R, Nardin M, Schaffer A, Barbieri L, et al. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor. J Thromb Haemost. 2016;14(1):57\u201364.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2018_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.amjcard.2019.11.033","volume":"125","author":"M Faggioni","year":"2020","unstructured":"Faggioni M, Redfors B, Crowley A, Claessen BE, Farhan S, Mastoris I, et al. Comparison of age (<75 years Vs >\/=75 years) and platelet reactivity to the risk of thrombotic and bleeding events after successful percutaneous coronary intervention with drug-eluting stents (from the ADAPT-DES study). Am J Cardiol. 2020;125(5):685\u201393.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2018_CR26","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/eurheartj\/ehr407","volume":"33","author":"J Silvain","year":"2012","unstructured":"Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, O'Connor SA, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012;33(10):1241\u20139.","journal-title":"Eur Heart J"},{"issue":"5","key":"2018_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MJT.0000000000000869","volume":"26","author":"E Bobescu","year":"2019","unstructured":"Bobescu E, Covaciu A, Rus H, Radoi M, Badea M, Moga SN, et al. Correlation of cardiovascular risk factors and biomarkers with platelet reactivity in coronary artery disease. Am J Ther. 2019;26(5):563\u20139.","journal-title":"Am J Ther"},{"issue":"8","key":"2018_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jacc.2013.09.070","volume":"63","author":"J Afilalo","year":"2014","unstructured":"Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014;63(8):747\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2018_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","volume":"141","author":"CN Floyd","year":"2014","unstructured":"Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther. 2014;141(1):69\u201378.","journal-title":"Pharmacol Ther"},{"issue":"23","key":"2018_CR30","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","volume":"34","author":"S Agewall","year":"2013","unstructured":"Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34(23):1708\u201313 1713a-1713b.","journal-title":"Eur Heart J"},{"issue":"3","key":"2018_CR31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12877-021-02018-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02018-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T05:09:54Z","timestamp":1611292194000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02018-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2018"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02018-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-64027\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-64027\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-64027\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-64027\/v1","asserted-by":"object"}]},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"21 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethical Review Committee of Peking University First Hospital. Administrative permissions from the Ethical Review Committee of Peking University First Hospital were required to access the raw data. The need for consent was waived because of the retrospective data.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}